Skip to content
Screener

Revolution Medicines, Inc. RVMD Other operating expenses

Other operating expenses at other companies

Erasca, Inc. logo
Erasca, Inc.ERAS
$187.91M+427%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$46.11M-30.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$137M-18.5%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$39.62M+21.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$99.07M-4.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$59.65M+26.0%

Other financials

Income statement

See full
Revenue-
Operating income-$505.1M-90.8%
Net income-$644.4M-160%
EPS (diluted)-$3.06-134%

Balance sheet

See full
Cash & equivalents$815.4M+103%
Total debt$154.5M+16.3%
Total equity$2.6B+39.7%
Total assets$4.3B+77.9%

Cash flow

See full
Operating cash flow-$387.3M-74.7%
CapEx$2.3M-69.3%
Free cash flow-$389.6M-70.0%

Valuation

See full
Market cap$44.36B+584%
Enterprise value$43.7B+603%

Profitability

See full
Operating margin-88,031.9%-89,488pp
Net margin-76,423.3%-77,733pp
FCF margin-74,273.9%-75,457pp

Returns & leverage

See full
Return on equity-79.1%+182pp
Debt / equity0.1×0.0×
Current ratio11.4×-0.4×

Where this comes from

Reported directly by Revolution Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Revolution Medicines, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:10 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335104
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Research and development$394,919$224,134$738,889$429,883
General and administrative110,21340,580211,46575,591
Total operating expenses505,132264,714950,354505,474
Loss from operations(505,132)(264,714)(950,354)(505,474)
Non-operating income (expense), net:
Interest income35,57922,40455,08747,319
Interest expense(23,781)(867)(35,978)(867)

Item 1. Financial Statements.

FAQ

What is Revolution Medicines, Inc.'s other operating expenses?
Revolution Medicines, Inc. (RVMD) reported other operating expenses of $505.13M in Q2 2026.
How has Revolution Medicines, Inc.'s other operating expenses changed year-over-year?
Revolution Medicines, Inc.'s other operating expenses increased by 90.8% year-over-year, from $264.71M to $505.13M.
What is the long-term trend for Revolution Medicines, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s other operating expenses has grown at a 52.7% compound annual growth rate (CAGR), from $217.4M to $1.18B.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about Revolution Medicines, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude